A Compartmental Pharmacokinetic Model with Linear and Nonlinear Elimination for Medical Cannabidiol Oil
Article Sidebar
Main Article Content
Abstract
This study presents the development of a compartmental model to describe the pharmacokinetics of cannabidiol (CBD) in medical cannabis oil following drug administration. The model incorporates both linear and nonlinear elimination based on Michaelis–Menten kinetics to represent urinary excretion and metabolic transformation of the drug. Ordinary differential equations were formulated based on the law of mass action to simulate the concentration–time relationships in each compartment and were solved numerically using MATLAB with the ode45 function. Pharmacokinetic parameters were estimated through curve fitting to clinical data. Simulation results demonstrate that the model-predicted plasma CBD concentrations are in close agreement with clinical data, with a peak concentration of approximately 1.45 ng/mL occurring at around 120 minutes. In addition, the estimated parameters can be applied to simulate drug concentrations in other compartments. This study is significant because it systematically links mechanistic understanding of CBD distribution and elimination with clinical applications. The developed model can serve as a supportive tool for dose determination and treatment planning, enabling the safe and effective clinical use of medical CBD oil.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The articles published are the opinion of the author only. The author is responsible for any legal consequences. That may arise from that article.
References
O. Devinsky, J. H. Cross, L. Laux, E. Marsh, I. Miller, R. Nabbout, I. E. Scheffer, E. A. Thiele, and S. Wright “Trial of cannabidiol for drugresistant seizures in the Dravet syndrome,” New England Journal of Medicine, vol. 376, no. 21, pp. 2011–2020, 2017, doi: 10.1056/ NEJMoa1611618.
L. Cuñetti, L. Manzo, R. Peyraube, J. Arnaiz, L. Curi, and S. Orihuela, “Chronic pain treatment with cannabidiol in kidney transplant patients in Uruguay,” Transplantation Proceedings, vol. 50, no. 2, pp. 461–464, 2018, doi: 10.1016/ j.transproceed.2017.12.042.
P. R. Gundugurti, N. Banda, S. S. R. Yadlapalli, A. Narala, R. Thatikonda, C. Kocherlakota, and K. S. Kothapalli, “Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double-blind, multicenter randomized clinical trial,” Asian Journal of Psychiatry, 2024, doi: 10.1016/j.ajp.2024.104073.
A. Lusawat, C. Khongkhatithum, S. Suwannachote, K. Katanyuwong, T. Fangsa-Ad, K. Anurat, S. Pattharathitikul, T. Thongmak, R. Thewamit, P. Sudachan, and A. Rojanawatsirivej, “National multicenter cohort study: Adjunctive cannabidiol-enriched cannabis oil for pediatric drug-resistant epilepsy treatment in Thailand,” Pediatric Neurology, vol. 169, pp. 59–68, 2025, doi: 10.1016/j.pediatrneurol.2025.04.015.
C. Aiewtrakoon, “Efficacy and safety of cannabidiol oil on chronic insomnia: The first randomized, double-blind, placebocontrolled, crossover pilot study in Thailand,” Journal of the Medical Association of Thailand, vol. 107, no. 3, pp. 160–170, 2024, doi: 10.35755/ jmedassocthai.2024.3.13952.
C. Monton, N. Chankana, S. Duangjit, J. Suksaeree, O. Naksuriya, L. Charoenchai, and T. Songsak, “Fabrication and optimization of directly compressible self-emulsifying tablets containing cannabis extract obtained from supercritical carbon dioxide extraction,” Applied Science and Engineering Progress, vol. 17, no. 1, 2024, doi: 10.14416/j.asep.2023.08.004
H. B. Schultz, A. Hosseini, A. J. McLachlan, and S. E. Reuter, “Population pharmacokinetics of oral-based administration of cannabidiol in healthy adults: Implications for drug development,” Cannabis and Cannabinoid Research, vol. 8, no. 5, pp. 877–886, 2023, doi: 10.1089/can.2021.0202.
A. R. Kolli and J. Hoeng, “Cannabidiol bioavailability is nonmonotonic with a long terminal elimination half-life: A pharmacokinetic modeling-based analysis,” Cannabis and Cannabinoid Research, 2025, doi: 10.1089/ can.2023.0214.
L. Michaelis, M. L. Menten, K. A. Johnson, and R. S. Goody, “The original Michaelis constant: Translation of the 1913 Michaelis-Menten paper,” Biochemistry, vol. 50, no. 39, pp. 8264– 8269, 2011, doi: 10.1021/bi201284u.
G. W. Guy and P. J. Robson, “A phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of Cannabis- Based Medicine Extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers (GWPK0215),” Journal of Cannabis Therapeutics, vol. 3, no. 4, pp. 121-152, 2014, doi: 10.1300/J175 v03n04_02.
S. A. Millar, N. L. Stone, A. Y. Yates, and S. E. O’Sullivan, “A systematic review on the pharmacokinetics of cannabidiol in humans,” Frontiers in Pharmacology, vol. 9, no. 1365, 2018, doi: 10.3389/fphar.2018.01365.
L. Taylor, D. Crockett, S. Tayo, and M. Morrison, “A phase 1, open-label, parallel-group, singledose trial of the pharmacokinetics and safety of cannabidiol (CBD) in subjects with mild to severe hepatic impairment,” Journal of Clinical Pharmacology, vol. 59, no. 8, pp. 1110–1119, 2019, doi: 10.1002/jcph.1403.
